REG - BkofA Merrill Lynch Horizon Therapeutics - 20230823_HORIZON THERAPEUTICS PLC_38.5 (b)_BOFAS

AmgenAnnouncement

24/08/2023 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230824:nRSX3625Ka&default-theme=true

RNS Number : 3625K  Bank of America Merrill Lynch  24 August 2023

FORM 38.5(b)

 

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2013

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT

RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED INTERMEDIARY

STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

 1.  KEY INFORMATION

 Name of exempt principal trader             BofA Securities, Inc.
 Company dealt in                            HORIZON THERAPEUTICS PLC
 Class of relevant security to which the     Common - IE00BQPVQZ61

dealings being disclosed relate(Note 1)
 Date of dealing                             23/08/2023

BofA Securities, Inc.

 Company dealt in

HORIZON THERAPEUTICS PLC

 Class of relevant security to which the

dealings being disclosed relate(Note 1)

Common - IE00BQPVQZ61

 Date of dealing

23/08/2023

 

 2.  INTERESTS AND SHORT POSITIONS

 (a)  Interests and short positions (following dealing) in the class of relevant
      security

dealt in (Note 2)

 Class of relevant security: Common             IE00BQPVQZ61
                                                Long             Short
                                                Number   %       Number   %
 (1)  Relevant securities                       215,158  0.094%  100,842  0.044%
 (2)  Derivatives (other than options):         165,032  0.072%  73,378   0.032%
 (3)  Options and agreements to purchase/sell:  30,000   0.013%  20,000   0.009%
 Total                                          410,190  0.179%  194,220  0.085%

215,158

0.094%

100,842

0.044%

 (2)  Derivatives (other than options):

165,032

0.072%

73,378

0.032%

 (3)  Options and agreements to purchase/sell:

30,000

0.013%

20,000

0.009%

Total

410,190

0.179%

194,220

0.085%

 

 (b)  Interests and short positions in relevant securities of the company, other
      than the

class dealt in (Note 2)

 Class of relevant security:
                                                Long         Short
                                                Number  %    Number  %
 (1)  Relevant securities                       0       0%   0       0%
 (2)  Derivatives (other than options):         0       0%   0       0%
 (3)  Options and agreements to purchase/sell:  0       0%   0       0%
 Total                                          0       0%   0       0%

0

0%

0

0%

 (2)  Derivatives (other than options):

0

0%

0

0%

 (3)  Options and agreements to purchase/sell:

0

0%

0

0%

Total

0

0%

0

0%

 3.  DEALINGS (Note 3)

 (a)  Purchases and sales

 Purchase/sale  Number of relevant securities  Price per unit (Note 4)
 Purchase       3,700                          105.468 USD
 Purchase       1                              106.12 USD

 

 Purchase/sale  Number of relevant securities  Price per unit (Note 4)
 Sale           1                              105.18 USD
 Sale           2                              105.33 USD
 Sale           2                              105.34 USD
 Sale           1                              105.45 USD
 Sale           2                              105.46 USD
 Sale           3,700                          105.772 USD
 Sale           28,711                         106.12 USD

 

 (b)  Derivatives transactions (other than options transactions)

 Product name,  Nature of transaction      Number of relevant securities  Price per unit

e.g. CFD
(Note 5)                  (Note 6)
(Note 4)
 Swaps          Closing a Short Position   3,700                          105.77 USD
 Swaps          Reducing a Short Position  28,237                         106.12 USD
 Swaps          Opening a Short Position   3,700                          105.469 USD

 

 (c)  Options transactions in respect of existing relevant securities

 (i)  Writing, selling, purchasing or varying

 Product name, e.g. call option  Writing, selling, purchasing, varying etc.  Number of securities to which the option relates (Note 7)  Exercise price  Type, e.g. American, European etc  Expiry date  Option money paid/ received per unit (Note 4)
 N/A                             N/A                                         N/A                                                        N/A             N/A                                N/A          N/A

 

 (ii)  Exercising

 Product name,      Number of securities  Exercise price per

e.g. call option
unit (Note 4)
 N/A                N/A                   N/A

 

 (d)  Other dealings (including transactions in respect of new securities) (Note 3)

 Nature or transaction  Details                   Price per unit
 (Note 7)
(if applicable) (Note 4)

 Borrow                 Borrow of 563,564 shares  N/A
 Loan                   Loan of 563,564 shares    N/A
 Borrow                 Borrow of 447,000 shares  N/A
 Borrow                 Borrow of 121,800 shares  N/A

 

 4.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 Full details of any agreement, arrangement or understanding between the person

disclosing and any other person relating to the voting rights of any relevant

securities under any option referred to on this form or relating to the voting
 rights

or future acquisition or disposal of any relevant securities to which any
 derivative

referred to on this form is referenced. If none, this should be stated.
 None

 

 Is a Supplemental Form 38.5(b) attached? (Note 8)  No

 

 Date of disclosure                            24/08/2023
 Contact name                                  Frank Lui
 Telephone number                              +44207 996 6418
 Name of offeree/offeror with which connected  AMGEN INC
 Nature of connection (Note 9)                 Advisor to - AMGEN INC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ITPKZGZRLDZGFZG